Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Review · February 15, 2017

A Review on PCSK9 Inhibition as a New Target for Cholesterol Management

Diabetologia

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetologia
PCSK9 Inhibition: The Dawn of a New Age in Cholesterol Lowering?
Diabetologia 2017 Mar 01;60(3)381-389, D Preiss, M Mafham

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading